ACTION ALERT: Sign this petition and ask Gilead CEO John C. Martin to stop the greed and withdraw the FDA application for Truvada as HIV prevention NOW.
Drug company Gilead Sciences Inc. is trying to ram Truvada - its successful HIV treatment medicine - as an HIV prevention pill through the U.S. Food & Drug Administration (FDA) approval process - despite serious concerns about the drug’s safety and effectiveness.
The multi-billion dollar profit Gilead is currently making on Truvada as an HIV treatment medication is not enough for them. Gilead now has its eyes on the billions of dollars that can be made by selling HIV drugs to people who don’t have the disease.
This is an act of desperation to protect unsustainably high profits from Truvada, which will go off-patent in the next few years. Truvada utilizes the same active ingredient (Tenofovir) as nearly all of the company’s other AIDS drugs. Gilead knows it doesn’t have the pipeline to replace its tenofovir-based drugs, so it’s doing everything it can to squeeze out more profit - even if that means putting healthy people at risk.
It’s time for Gilead to stop the greed and withdraw its FDA application for Truvada as pre-exposure prophylaxis (PrEP) - or HIV prevention pill - NOW.
Stop Squeezing Every Last Cent Out of Truvada
Dear Gilead CEO John C. Martin,
I am concerned that Gilead Sciences Inc. is trying to ram Truvada its successful HIV treatment medicine as an HIV prevention pill through the U.S. Food & Drug Administration (FDA) approval process--despite serious concerns about the drug's safety and effectiveness.
The multi-billion dollar profit Gilead is currently making on Truvada as an HIV treatment medication is not enough. Gilead now has its eyes on the billions of dollars that can be made by selling HIV drugs to people who don't have the disease.
This is an act of desperation to protect unsustainably high profits from Truvada, which will go off-patent in the next few years. Truvada utilizes the same active ingredient (Tenofovir) as nearly all of the company's other AIDS drugs. Gilead knows it doesn't have the pipeline to replace its tenofovir-based drugs, so it's doing everything it can to squeeze out more profit--even if that means putting healthy people at risk.
Mr. Martin, it's time for Gilead to stop the greed and withdraw its FDA application for Truvada as pre-exposure prophylaxis (PrEP)--or HIV prevention pill--NOW.
I look forward to your immediate action on this urgent public health matter.
